Belite Bio Inc American Depositary Shares (BLTE)

FairStock Score: 16/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

As a value investor, I start with what is knowable: Belite Bio is a clinical-stage biopharmaceutical company with 41 employees, no marketed product, and a lead candidate, Tinlarebant, in Phase 3 for Stargardt disease type 1 and geographic atrophy. That is a lottery ticket tied to clinical outcomes, not a business with durable earnings. The absence of a Peter Lynch category, because there are zero years of filed annual results, underscores how early this story is. Financially, the firm has no debt, D/E of 0.00, which is a genuine strength; but FairStock calculations show a P/B of 7.87, ROE of -22.10%, ROCE of -15.65%, and a negative P/E of -55.43 as of the 2026-10-13 close. The Piotroski F-Score is 0/9, and the FairStock Score is 16/100. The high Altman Z-Score of 267.87 is not evidence of operating quality; it reflects a balance sheet with no debt, not a profitable business. At a $6.7B market cap and $151.87 price, investors are already paying a large sum for future trial success. Graham would demand a margin of safety in assets or earnings; here there are no earnings and P/B is nearly 8x. Buffett would ask about a moat; none is evident in a pre-revenue biotech with binary regulatory risk. Growth is not revenue growth; it is pipeline progress. I can admire the unmet medical need, but I cannot call this a value investment based on the figures. The stock is a speculative clinical bet, not a Graham-style bargain.

In plain English: Belite Bio is a small clinical-stage drug developer working on an oral medicine for serious retinal diseases, with no product on the market and no meaningful revenue. The business looks weak on current financial measures because it loses money, has negative returns, and has very little filed financial history, though it carries no debt. After the 2026-10-13 close at $151.87, the price looks expensive against today's numbers because there are no profits to support it.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer